Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe

Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe

BACKGROUND: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region. METHODS: Between November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of puta...

Full description

Saved in:
Bibliographic Details
Main Authors: O. Kirakosyan, M. Reimann, A.B. Andersen, A. Bjarnason, Á. Bakos, A.M. Dyrhol-Riise, A.M. McLaughlin, C. Nita, D. Pieridou, D. Chesov, E.V. Davidavičienė, G. Günther, H. Atshemyan, I. Muylle, I. Solovic, J. Bruchfeld, K. Manika, L. Kuksa, L.R. Codecasa, M. Stosic, M. Skowroński, M.J. Makek, M. Fréchet Jachym, M. Knappik, M. Santin, N. Yatskevich, O. Konstantynovska, O. Akkerman, P. Svetina, P. Viiklepp, R. Duarte, S. Zeynel, T. Togonidze, T. Vasankari, V. Parris, Ş. Özkara, C. Lange, T.T. Brehm
Format: Article
Language:English
Published: International Union Against Tuberculosis and Lung Disease (The Union) 2025-02-01
Series:IJTLD Open
Subjects:
hepatotoxicity
drug-induced liver injury
hepatitis
silibinin
ursodeoxycholic acid
Online Access:https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000002/art00008
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2025/00000002/00000002/art00008

Similar Items